MedTrace Logo

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

NCT04938180 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-05-24

Study results available
· View outcomes & findings →

Summary

The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of subjects with TGCT.

Conditions

  • Tenosynovial Giant Cell Tumor
  • Pigmented Villonodular Synovitis
  • TGCT
  • PVNS - Pigmented Villonodular Synovitis

Interventions

BIOLOGICAL

AMB-05X

AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R

Sponsors & Collaborators

  • AmMax Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Dorothy Nguyen, MD · AmMax Bio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2022-04-20
Completion
2022-05-17
FDA Drug
Yes

Countries

  • Hungary
  • Poland
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938180 on ClinicalTrials.gov